Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice.

Ramakrishnan S, Huss W, Foster B, Ohm J, Wang J, Azabdaftari G, Eng KH, Woloszynska-Read A.

Am J Clin Exp Urol. 2018 Jun 15;6(3):138-148. eCollection 2018.

2.

Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Reveals Changes in the Insulin-like Growth Factor Signaling Pathway.

Tu C, Fiandalo MV, Pop E, Stocking JJ, Azabdaftari G, Li J, Wei H, Ma D, Qu J, Mohler JL, Tang L, Wu Y.

J Proteome Res. 2018 Sep 7;17(9):2963-2977. doi: 10.1021/acs.jproteome.8b00135. Epub 2018 Aug 3.

PMID:
30014700
3.

Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.

Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, Attwood KM, Azabdaftari G, Wu Y, Watt DS, Wilson EM, Mohler JL.

Oncotarget. 2018 Jan 10;9(13):11227-11242. doi: 10.18632/oncotarget.24107. eCollection 2018 Feb 16.

4.

Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.

Gocher AM, Azabdaftari G, Euscher LM, Dai S, Karacosta LG, Franke TF, Edelman AM.

J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.

5.

Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.

Nunez Bragayrac LA, Murekeyisoni C, Vacchio MJ, Attwood K, Mehedint DC, Mohler JL, Azabdaftari G, Xu B, Kauffman EC.

Prostate. 2017 Jul;77(10):1076-1081. doi: 10.1002/pros.23364. Epub 2017 May 26.

PMID:
28547760
6.

Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, Osborne JR, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA.

Cancer Discov. 2017 Sep;7(9):973-983. doi: 10.1158/2159-8290.CD-16-0960. Epub 2017 May 17.

7.

Characterization of Prostate Cancer in a Functional Eunuch.

Stocking JJ, Fiandalo MV, Pop EA, Wilton JH, Azabdaftari G, Mohler JL.

J Natl Compr Canc Netw. 2016 Sep;14(9):1054-60.

8.

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.

Shourideh M, Azabdaftari G, Attwood K, DePriest A, Wadosky KM, Gillard BM, Karasik E, Heemers H, Kyprianou N, Gelman IH, Corey E, Vessella RL, Mohler JL, Koochekpour S.

Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016. doi: 10.1158/1078-0432.CCR-16-0137. [Epub ahead of print] Retraction in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3973.

PMID:
27458247
9.

Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, Gomez EC, Murakam M, Glenn ST, Conroy J, Morrison C, Azabdaftari G, Mohler JL, Liu S, Heemers HV.

Eur Urol. 2017 Feb;71(2):183-192. doi: 10.1016/j.eururo.2016.07.008. Epub 2016 Jul 21.

10.

Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer.

Ellis L, Ku S, Li Q, Azabdaftari G, Seliski J, Olson B, Netherby CS, Tang DG, Abrams SI, Goodrich DW, Pili R.

Prostate. 2016 Sep;76(13):1192-202. doi: 10.1002/pros.23206. Epub 2016 May 26.

11.

Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.

Doshi C, Vacchio M, Attwood K, Murekeyisoni C, Mehedint DC, Badkhshan S, Azabdaftari G, Sule N, Guru KA, Mohler JL, Kauffman EC.

Prostate. 2016 Jun;76(8):715-21. doi: 10.1002/pros.23166. Epub 2016 Feb 16.

12.

Metastatic phenotype in CWR22 prostate cancer xenograft following castration.

Seedhouse SJ, Affronti HC, Karasik E, Gillard BM, Azabdaftari G, Smiraglia DJ, Foster BA.

Prostate. 2016 Mar;76(4):359-68. doi: 10.1002/pros.23127. Epub 2015 Dec 8.

13.

Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.

Karacosta LG, Kuroski LA, Hofmann WA, Azabdaftari G, Mastri M, Gocher AM, Dai S, Hoste AJ, Edelman AM.

Prostate. 2016 Feb 15;76(3):294-306. doi: 10.1002/pros.23121. Epub 2015 Nov 10.

PMID:
26552607
14.

Intake of dietary antioxidants is inversely associated with biomarkers of oxidative stress among men with prostate cancer.

Vance TM, Azabdaftari G, Pop EA, Lee SG, Su LJ, Fontham ET, Bensen JT, Steck SE, Arab L, Mohler JL, Chen MH, Koo SI, Chun OK.

Br J Nutr. 2016 Jan 14;115(1):68-74. doi: 10.1017/S0007114515004249. Epub 2015 Nov 2.

PMID:
26521663
15.

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.

Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, Levine EG, Azabdaftari G, Trump DL, Guru K, George S.

Clin Genitourin Cancer. 2016 Feb;14(1):e59-65. doi: 10.1016/j.clgc.2015.09.013. Epub 2015 Oct 3.

PMID:
26508364
16.

Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants.

Vance TM, Azabdaftari G, Pop EA, Lee SG, Su LJ, Fontham ET, Bensen JT, Steck SE, Arab L, Mohler JL, Chen MH, Koo SI, Chun OK.

Prostate Cancer. 2015;2015:728046. doi: 10.1155/2015/728046. Epub 2015 Aug 18.

17.

Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue.

Payne Ondracek R, Cheng J, Gangavarapu KJ, Azabdaftari G, Woltz J, Brese E, Omilian A, Bshara W, Huss WJ, Mohler JL, Marshall JR.

Prostate. 2015 Dec;75(16):1910-5. doi: 10.1002/pros.23087. Epub 2015 Sep 9.

18.

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.

Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R.

Oncogene. 2016 Mar 24;35(12):1541-53. doi: 10.1038/onc.2015.219. Epub 2015 Jun 29.

19.

Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy.

Cheng J, Ondracek RP, Mehedint DC, Kasza KA, Xu B, Gill S, Azabdaftari G, Yao S, Morrison CD, Mohler JL, Marshall JR.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):182-9. doi: 10.1038/pcan.2015.11. Epub 2015 Apr 14.

20.

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.

Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L.

Oncotarget. 2015 Feb 20;6(5):3136-46.

21.

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis.

Ellis L, Lehet K, Ku S, Azabdaftari G, Pili R.

Oncoscience. 2014 Oct 15;1(10):609-613.

22.

Clinicopathologic characterization of intradiverticular carcinoma of urinary bladder - a study of 22 cases from a single cancer center.

Zhong H, George S, Kauffman E, Guru K, Azabdaftari G, Xu B.

Diagn Pathol. 2014 Nov 26;9:222. doi: 10.1186/s13000-014-0222-8.

23.

Establishment and characterization of a highly tumorigenic African American prostate cancer cell line, E006AA-hT.

Koochekpour S, Willard SS, Shourideh M, Ali S, Liu C, Azabdaftari G, Saleem M, Attwood K.

Int J Biol Sci. 2014 Jul 26;10(8):834-45. doi: 10.7150/ijbs.9406. eCollection 2014.

24.
25.

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.

Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R.

Oncotarget. 2013 Dec;4(12):2225-36.

26.

Human prostate side population cells demonstrate stem cell properties in recombination with urogenital sinus mesenchyme.

Foster BA, Gangavarapu KJ, Mathew G, Azabdaftari G, Morrison CD, Miller A, Huss WJ.

PLoS One. 2013;8(1):e55062. doi: 10.1371/journal.pone.0055062. Epub 2013 Jan 31.

27.

Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells.

Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, Manhardt C, Lorusso GD, Willard SS, Thompson H, Shourideh M, Rezaei K, Sartor O, Mohler JL, Vessella RL.

Clin Cancer Res. 2012 Nov 1;18(21):5888-901. doi: 10.1158/1078-0432.CCR-12-1308. Epub 2012 Oct 16.

28.

A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.

Karacosta LG, Foster BA, Azabdaftari G, Feliciano DM, Edelman AM.

J Biol Chem. 2012 Jul 13;287(29):24832-43. doi: 10.1074/jbc.M112.370783. Epub 2012 May 31.

29.

Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.

Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, Azabdaftari G, Nakaso K, Yan Z, Feng J.

Nat Commun. 2012 Feb 7;3:668. doi: 10.1038/ncomms1669.

30.

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.

Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R.

Mol Cancer Ther. 2012 Feb;11(2):383-92. doi: 10.1158/1535-7163.MCT-11-0748. Epub 2011 Nov 14.

31.

Serum prosaposin levels are increased in patients with advanced prostate cancer.

Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Zhu G, Zhau HE, Chung LW, Vessella RL.

Prostate. 2012 Feb;72(3):253-69. doi: 10.1002/pros.21427. Epub 2011 May 31. Erratum in: Prostate. 2014 May;74(7):804.

32.

Efficacy of on-site specimen adequacy evaluation of image-guided fine and core needle biopsies.

Azabdaftari G, Goldberg SN, Wang HH.

Acta Cytol. 2010 Mar-Apr;54(2):132-7.

PMID:
20391967
33.

Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.

Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G, Sharifi S, Kuliopulos A.

Mol Cancer Ther. 2008 Sep;7(9):2746-57. doi: 10.1158/1535-7163.MCT-08-0177.

34.

S100 protein expression distinguishes metanephric adenomas from other renal neoplasms.

Azabdaftari G, Alroy J, Banner BF, Ucci A, Bhan I, Cheville JC.

Pathol Res Pract. 2008;204(10):719-23. doi: 10.1016/j.prp.2008.04.013. Epub 2008 Jul 14.

PMID:
18621486
35.

Impact of model for end-stage liver disease (MELD) scoring system on pathological findings at and after liver transplantation.

Khettry U, Azabdaftari G, Simpson MA, Pomfret EA, Pomposelli JJ, Lewis WD, Jenkins RL, Gordon FD.

Liver Transpl. 2006 Jun;12(6):958-65.

36.

Excellent outcome following transplantation of a domino donor liver with high-grade macrosteatosis.

Azabdaftari G, Pomfret EA, Simpson MA, Pomposelli JJ, Lewis WD, Jenkins RL, Gordon FD, Khettry U.

Pathol Res Pract. 2004;200(7-8):581-7; discussion 589-90.

PMID:
15462507

Supplemental Content

Loading ...
Support Center